Setmelanotide for Obesity in One Person With Pseudohypoparathyroidism Type 1a
Tests setmelanotide for obesity in one person with pseudohypoparathyroidism type 1a.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 1 person, planned
- Started
- 21 Jul 2026
- Expected to end
- 30 Apr 2027
- Type of study
- Interventional
- Treatments tested
- Setmelanotide
- Record updated
- 23 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for one patient with pseudohypoparathyroidism type 1a (PHP1a) and obesity, to test setmelanotide for 6 months.
- Sex
- All sexes can join.
- Disease stage
- Known PHP1a with a confirmed GNAS mutation, and obesity.
- Earlier treatment
- Diabetes and high blood fat (dyslipidemia) must already be on optimized therapy.
- Biomarker or test result
- A confirmed GNAS mutation.
Main reasons for not taking part
- Taking medicines that may affect the trial results and that were changed within 3 months before the start
- Taking medicines that are likely to need a dose change during the 6-month treatment
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Known patient with PHP1a (confirmed GNAS mutation)
- Optimized therapy for diabetes and dyslipidemia
Who cannot take part
- Use of medications that may affect endpoints that are changed within 3 months prior to Baseline or that are likely to require a change in dose during the open-label treatment period
Where in United States
- Massachusetts General HospitalBoston, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.
The group in the trial
- Patient with pseudohypoparathyroidism type 1aOther group
A preselected patient with obesity related to pseudohypoparathyroidism type 1a.
Treatment: Setmelanotide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
- Plain-language title
- Setmelanotide for Obesity in One Person With Pseudohypoparathyroidism Type 1aGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 23 July 2026